10th Conference on DNA Topoisomerases in therapy

Drug Resistance Updates

Volumn 2, Issue 6, 1999, Pages 347-350

  Giaccone, Giuseppe ^a   Capranico, Giovanni ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Camptothecins; DNA topoisomerase I; DNA topoisomerase II; Meeting

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IRINOTECAN; MITOXANTRONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TENIPOSIDE; TOPOTECAN;

CANCER; CANDIDA ALBICANS; CHROMATIN; DRUG DNA INTERACTION; DRUG SENSITIVITY; DRUG SOLUBILITY; ENZYMOLOGY; KNOCKOUT MOUSE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

EID: 0033502771     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0109     Document Type: Article

References (11)

1. Redinbo M. R., Champoux J. J., Hol W. G. Structural insights into the function of type IB topoisomerases. Curr Opin Struct Biol. 9:1999;29-36.
2. Redinbo M. R., Stewart L., Champoux J. J., Hol W. G. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J Mol Biol. 292:1999;685-696.
3. Poot M., Gollahon K. A., Rabinovitch P. S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet. 104:1999;10-14.
4. Beretta G. L., Binaschi M., Zagni E., Capuani L., Capranico G. Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain. Cancer Res. 59:1999;3689-3697.
5. Shao R. G., Cao C. X., Zhang H., Kohn K. W., Wold M. S., Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J. 18:1999;1397-1406.
6. Reid R. J., Fiorani P., Sugawara M., Bjornsti M. A. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc Natl Acad Sci U S A. 96:1999;11440-11445.
7. Mao Y., Yu C., Hsieh T. S. Mutations of human topoisomerase II alpha affecting multidrug resistance and senstivity. Biochemistry. 38:1999;10793-10800.
8. Rougier P., Van Cutsem E., Bajetta E. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
9. Cunningham D., Pyrhonen S., James R. D. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
10. Capranico G., Giaccone G., D'Incalci M. DNA topoisomerase II poisons and inhibitors. Pinedo H. M., Longo D. L., Chabner B. A. Cancer chemotherapy and biological response modifiers Annual vol. 18. 1999;126-144 Elsevier Science Publs.
11. Hooper D. C. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis. 27 (Suppl 1):1998;S54-S63.